ResearcherMarmara UniversityActive in the last 2 years

Nargız Majidova

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2575-5819; OpenAlex author ID A5015956321. Sources: OpenAlex.

Their work

Papers: 3 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 9

Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 3

Correction: Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. Co-author DOI 10.1038/s41598-026-47335-7 ↗
Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. Co-author DOI 10.1038/s41598-025-96157-6 ↗
Is diabetes onset at advanced age a sign of pancreatic cancer? Last author PMID 36156490 ↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Melike Özçelik · 2 shared papers, 2025–2026 · strength 0.34
- Paper Correction: Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. DOI 10.1038/s41598-026-47335-7 ↗
- Paper Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. DOI 10.1038/s41598-025-96157-6 ↗
İlkay Gültürk · 2 shared papers, 2025–2026 · strength 0.34
- Paper Correction: Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. DOI 10.1038/s41598-026-47335-7 ↗
- Paper Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. DOI 10.1038/s41598-025-96157-6 ↗
Abdullah Sakin · 2 shared papers, 2025–2026 · strength 0.34
- Paper Correction: Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. DOI 10.1038/s41598-026-47335-7 ↗
- Paper Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. DOI 10.1038/s41598-025-96157-6 ↗
Yasin Sezgin · 2 shared papers, 2025–2026 · strength 0.34
- Paper Correction: Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. DOI 10.1038/s41598-026-47335-7 ↗
- Paper Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. DOI 10.1038/s41598-025-96157-6 ↗
Bilgin Demir · 2 shared papers, 2025–2026 · strength 0.34
- Paper Correction: Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. DOI 10.1038/s41598-026-47335-7 ↗
- Paper Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. DOI 10.1038/s41598-025-96157-6 ↗
Yakup Ergün · 2 shared papers, 2025–2026 · strength 0.34
- Paper Correction: Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. DOI 10.1038/s41598-026-47335-7 ↗
- Paper Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. DOI 10.1038/s41598-025-96157-6 ↗
Oğuzhan Özşay · 1 shared paper, 2022 · strength 0.22
- Paper Is diabetes onset at advanced age a sign of pancreatic cancer? PMID 36156490 ↗
Şirin Çetin · 1 shared paper, 2022 · strength 0.22
- Paper Is diabetes onset at advanced age a sign of pancreatic cancer? PMID 36156490 ↗
Mustafa Yıldırım · 1 shared paper, 2025 · strength 0.16
- Paper Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. DOI 10.1038/s41598-025-96157-6 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.